DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

454 Mahmoud RA, Pandina GJ, Turkoz I, et al. Risperidone for
treatment- refractory major depressive disorder: A randomized
trial. Ann Intern Med, 2007, 147:593–602.
Mamo D, Graff A, Mizrahi R, et al. Differential effects of aripiprazole
on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy
in patients with schizophrenia: A triple tracer PET study.
Am J Psychiatry, 2007, 164:1411–1417.
Mamo D, Kapur S, Shammi CM, et al. A PET study of dopamine
D2 and serotonin 5-HT2 receptor occupancy in patients with
schizophrenia treated with therapeutic doses of ziprasidone.
Am J Psychiatry, 2004, 161:818–825.
Mamo DC, Uchida H, Vitcu I, et al. Quetiapine extended-release
versus immediate- release formulation: A positron emission
tomography study. J Clin Psychiatry, 2008, 69:81–86.
Mangano WE, Montine TJ, Hulette CM. Pathologic assessment
of cerebellar atrophy following acute lithium intoxication. Clin
Neuropathol, 1997, 16:30–33.
Manji HK, Chen G. PKC, MAP kinases and the bcl-2 family of
proteins as long- term targets for mood stabilizers. Mol
Psychiatry, 2002, 7(Suppl 1):S46–S56.
Manji HK, Lenox RH. Signaling: Ccellular insights into the
pathophysiology of bipolar disorder. Biol Psychiatry, 2000,
48:518–530.
Marek GJ, Carpenter LL, McDougle CJ, Price LH. Synergistic action
of 5-HT2A antagonists and selective serotonin reuptake inhibitors
in neuropsychiatric disorders. Neuropsychopharmacology, 2003,
28:402–412.
McDougle CJ, Epperson CN, Pelton GH, et al. A double- blind,
placebo- controlled study of risperidone addition in serotonin
reuptake inhibitor- refractory obsessive- compulsive disorder.
Arch Gen Psychiatry, 2000, 57:794–801.
McMahon FJ, Buervenich S, Charney D, et al. Variation in the
gene encoding the serotonin 2A receptor is associated with
outcome of antidepressant treatment. Am J Hum Genet, 2006,
78:804–814.
Meyer JM. Effects of atypical antipsychotics on weight and
serum lipid levels. J Clin Psychiatry, 2001, 62(Suppl 27):
27–34; discussion 40–21.
Meyer JM. A retrospective comparison of weight, lipid, and glucose
changes between risperidone- and olanzapine- treated
inpatients: Metabolic outcomes after 1 year. J Clin Psychiatry,
2002, 63:425–433.
Meyer JM. Drug- drug interactions with antipsychotics. CNS
Spectrums, 2007, 12:6–9.
Meyer JM, Davis VG, Goff DC, et al. Change in metabolic syndrome
parameters with antipsychotic treatment in the CATIE
Schizophrenia Trial: Prospective data from phase 1.
Schizophrenia Res, 2008, 101:273–286.
Meyer JM, Dollarhide A, Tuan IL. Lithium toxicity after switch
from fosinopril to lisinopril. Int Clin Psychopharmacol, 2005,
20:115–118.
Meyer JM, Koro CE. The effects of antipsychotic therapy on
serum lipids: A comprehensive review. Schizophrenia Res,
2004, 70:1–17.
Meyer JM, Nasrallah HA, eds. Medical Illness and Schizophrenia,
2nd ed. American Psychiatric Press, Washington, D.C., 2009.
Meyer JM, Schweizer E. Lurasidone: A new drug in development
for schizophrenia. Expert Opin Inves Drugs, 2009, 18:1–12.
Morriss R, Benjamin B. Lithium and eGFR: A new routinely
available tool for the prevention of chronic kidney disease. Br
J Psychiatry, 2008, 193:93–95.
SECTION II
NEUROPHARMACOLOGY
Need AC, Ge D, Weale ME, et al. A genome-wide investigation
of SNPs and CNVs in schizophrenia. PLoS Genetics, 2009,
5:e1000373.
Newport DJ, Viguera AC, Beach AJ, et al. Lithium placental passage
and obstetrical outcome: Implications for clinical management
during late pregnancy. Am J Psychiatry, 2005,
162:2162–2170.
Nielsen J, Toft E. The spectrum of cardiovascular disease in
schizophrenia. In, Medical Illness and Schizophrenia, 2nd ed.
(Meyer JM, Nasrallah HA, eds.) American Psychiatric Press,
Washington, D.C., 2009, pp. 187–228.
Otani K, Aoshima T. Pharmacogenetics of classical and new
antipsychotic drugs. Ther Drug Monitor, 2000, 22:
118–121.
Patil ST, Zhang L, Martenyi F, et al. Activation of mGlu2/3
receptors as a new approach to treat schizophrenia: A randomized
phase 2 clinical trial. Nat Med, 2007, 13:1102–1107.
Phelan KM, Mosholder AD, Lu S. Lithium interaction with the
cyclooxygenase 2 inhibitors rofecoxib and celecoxib and other
nonsteroidal anti-inflammatory drugs. J Clin Psychiatry, 2003,
64:1328–1334.
Porteous D. Genetic causality in schizophrenia and bipolar disorder:
out with the old and in with the new. Curr Opin Genet
Dev, 2008, 18:229–234.
Post RM, Ketter TA, Uhde T, Ballenger JC. Thirty years of clinical
experience with carbamazepine in the treatment of bipolar
illness: Principles and practice. CNS Drugs, 2007, 21:
47–71.
Quiroz JA, Gould TD, Manji HK. Molecular effects of lithium.
Mol Interven, 2004, 4:259–272.
Rao JS, Lee HJ, Rapoport SI, Bazinet RP. Mode of action of
mood stabilizers: Is the arachidonic acid cascade a common
target? Mol Psychiatry, 2008, 13:585–596.
Rapoport SI, Bosetti F. Do lithium and anticonvulsants target the
brain arachidonic acid cascade in bipolar disorder? Arch Gen
Psychiatry, 2002, 59:592–596.
Rauser L, Savage JE, Meltzer HY, Roth BL. Inverse agonist
actions of typical and atypical antipsychotic drugs at the
human 5-hydroxytryptamine(2C) receptor. J Pharmacol Exp
Ther, 2001, 299:83–89.
Ray WA, Chung CP, Murray KT, et al. Atypical antipsychotic
drugs and the risk of sudden cardiac death. N Engl J Med,
2009, 360:225–235.
Rosenheck RA, Leslie DL, Sindelar J, et al. Cost-effectiveness
of second- generation antipsychotics and perphenazine in a randomized
trial of treatment for chronic schizophrenia. Am J
Psychiatry, 2006, 163:2080–2089.
Rostami- Hodjegan A, Amin AM, Spencer EP, et al. Influence of
dose, cigarette smoking, age, sex, and metabolic activity on
plasma clozapine concentrations: A predictive model and
nomograms to aid clozapine dose adjustment and to assess
compliance in individual patients. J Clin Psychopharmacol,
2004, 24:70–78.
Rothschild AJ, Williamson DJ, Tohen MF, et al. A double-blind,
randomized study of olanzapine and olanzapine/fluoxetine
combination for major depression with psychotic features.
J Clin Psychopharmacol, 2004, 24:365–373.
Scherk H, Pajonk FG, Leucht S. Second- generation antipsychotic
agents in the treatment of acute mania: A systematic
review and meta- analysis of randomized controlled trials. Arch
Gen Psychiatry, 2007, 64:442–455.